From the Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Circ Res. 2020 May 8;126(10):1443-1455. doi: 10.1161/CIRCRESAHA.120.317055. Epub 2020 Apr 7.
Infection with the severe acute respiratory syndrome novel coronavirus produces a clinical syndrome known as 2019 novel coronavirus disease (COVID-19). When severe, COVID-19 is a systemic illness characterized by hyperinflammation, cytokine storm, and elevations of cardiac injury biomarkers. Here, we review what is known about the pathophysiology of COVID-19, its cardiovascular manifestations, and emerging therapeutic prospects. In this rapidly moving field, this review was comprehensive as of April 3, 2020.
感染严重急性呼吸综合征新型冠状病毒会产生一种被称为 2019 年新型冠状病毒病(COVID-19)的临床综合征。当病情严重时,COVID-19 是一种全身性疾病,其特征是过度炎症、细胞因子风暴以及心肌损伤生物标志物升高。在这里,我们回顾了 COVID-19 的病理生理学、心血管表现以及新兴治疗前景。在这个快速发展的领域,本综述截至 2020 年 4 月 3 日是全面的。
Circ Res. 2020-4-7
Circulation. 2020-3-21
Circulation. 2020-4-16
Hellenic J Cardiol. 2020
Heart Lung Circ. 2020-6-5
Pharmacol Res. 2020-9
Arq Bras Cardiol. 2020-4
Nat Rev Cardiol. 2020-5
Biomed Pharmacother. 2020-9-9
J Clin Med. 2025-6-27
Signal Transduct Target Ther. 2025-4-16
GHM Open. 2021-8-31
Front Artif Intell. 2025-3-12
BMC Nephrol. 2024-11-12
J Multidiscip Healthc. 2024-11-1